Neuro-Degenerative Disease Clinical Trial
— [11C]ButanolOfficial title:
Characterizing the Safety of [Carbon-11]Butanol and Estimating the Test-Retest Variance in Measurements of Its Whole Body Biokinetics Under Zero-Biological-Change Conditions
Verified date | June 2021 |
Source | Weill Medical College of Cornell University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This will be a Phase 1, open label, imaging study of radiochemical and radiation safety in healthy volunteers. Using positron emission tomography (PET) and in-line computed tomography (CT), the whole body (WB) biokinetics of Carbon-11 butanol will be quantified with serial scans acquired every 3 minutes for two hours. Vital signs (VS), electrocardiograms (ECGs) and clinical laboratory tests of intrernal organ function will be acquired before and at several timepoints after administration of the radiopharmaceutical. Radiation exposures will be estimated with the MIRD Formalism.
Status | Completed |
Enrollment | 5 |
Est. completion date | January 5, 2021 |
Est. primary completion date | December 29, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: - able to give informed consent. - age 18-89 - Subjectively healthy and, in the opinion of the investigators, likely to tolerate the imaging procedures and be compliant with the schedule of follow up telephone calls. - Normal hemodynamic function. Systolic blood pressure and pulse must be higher than 120 mmHg and 60 beats per minute while sitting. At the discretion of the investigators, people who regularly engage in vigorous exercise more than four times per week may be enrolled if their systolic blood pressure and pulse are higher than 100 mmHg and 50 beats per minute while sitting. - Unremarkable electrocardiograms, with PR intervals of less than 200 mSec and QTcF intervals (corrected with Frederica's method) of less than 440 mSec. - No concurrent medications with the exception of p.r.n. NSAIDS, which must be discontinued one week prior to PET scanning. - Willing and able to refrain from abusing any recreational drugs, including marijuana, and drink less than one unit of alcoholic beverages per day starting one week prior to PET scanning, and avoided for the next four weeks. - Willing to refrain from donating blood for four (4) weeks before the study and for four (4) weeks after the study. - Willing to refrain from participating in any other research study that requires taking medication for four (4) weeks before the study and for four (4) weeks after the study. - Willing to refrain from being vaccinated for four (4) weeks before the study and for four (4) weeks after the study. - All clinical laboratory test results within normal limits or not clinically significant. For example, elevated bilirubin levels in subjects with Gilbert's syndrome will be allowed, as will small red blood cell volumes in healthy people with sickle cell trait. Exclusion Criteria: - Subjects may not be a member of a vulnerable population. - Women may not be pregnant or breast feeding. - History of multiple hypersensitivity reactions (atopia), as indicated by allergies to multiple medications, foods, and seasonal pollens. - History, physical examination, or clinical laboratory tests suggestive of a condition, disorder, or disease that could adversely affect drug absorption, distribution, metabolism, or elimination (ADME) of the tracer, including chronic liver or renal failure. - Positive urine toxicology screen for recreational drugs other than marijuana. - May not have taken any controlled medications, including other study drugs, in the 30 days prior to PET scanning or for 10 half-lives, whichever is longer. - May not have donated blood in the 30 days prior to PET scanning. - May not have participated in research administering drugs in the last 30 days. - May not have been vaccinated in the 30 days prior to PET scanning. - May not have been exposed to radiation during research of more than 10 mSv during the last year. |
Country | Name | City | State |
---|---|---|---|
United States | Weill Cornell Medicine | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effective Dose (ED) | Fundamental radiation dose quantity in the International Commission on Radiological Protection (ICRP) system of radiological protection. Calculated with OLINDA-EXM software (OLINDA/EXM stands for Organ Level INternal Dose Assessment/EXponential Modeling). | Day 1, from the measurements of exposures during the first 2 hours post administration. | |
Secondary | Change in Radiochemical Safety Assessments | Change in pulse | Pulse at two hours post administration compared to pulse shortly before administration. | |
Secondary | Change in Radiochemical Safety Assessments | Change in blood pressure | Blood pressure at two hours post administration compared to blood pressure shortly before administration. | |
Secondary | Change in Radiochemical Safety Assessments | Change in heart rhythm on electrocardiogram (ECG) | At two hours post administration compared to same parameters shortly before administration. | |
Secondary | Change in number of Subjects with prolonged PR interval greater than 20 mSec | Change in PR interval on electrocardiogram (ECG) | At two hours post administration compared to same parameters shortly before administration. | |
Secondary | Change in number of subjects with QTc >440 mSec | Change in corrected QT interval on electrocardiogram (ECG). | At two hours post administration compared to same parameters shortly before administration. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05586750 -
Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
|
Phase 4 | |
Recruiting |
NCT04863859 -
Persons With Dementia and Their Extended Family Caregivers
|
||
Recruiting |
NCT05655650 -
Identifying Biomarkers in Alzheimer's Disease
|
||
Completed |
NCT04937127 -
Efficiency of E-learning and Role-playing for the Training of Nursing Home Caregivers in the Support of Agitation in Neurodegenerative Diseases
|
||
Enrolling by invitation |
NCT03197363 -
BiaĆystok PLUS - Polish Longitudinal University Study
|
||
Enrolling by invitation |
NCT03322306 -
Establishment of Genetic Basis for Neurological Disease by Genetic Screening
|
||
Completed |
NCT03439163 -
Large Sample PD Patients and Healthy Controls
|
N/A | |
Withdrawn |
NCT05921929 -
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
|
Phase 1 | |
Recruiting |
NCT05209698 -
Self-Management Behaviors of Arabs and Jews With Parkinson's Disease and Their Associations With Health Outcomes
|
||
Completed |
NCT04362228 -
The Effects of Whole-body Exercise to Improve Swallowing Function in Older Adults With Dementia
|
N/A | |
Enrolling by invitation |
NCT05008094 -
The Epidemiology of Parkinson's Disease in Croatia and the Influence of Genetic Factors and Microbiota on the Progression and Treatment Outcomes of the Disease (GiOPARK)
|
||
Completed |
NCT03279991 -
Neuromed- Integrated Health Life Platform and Biobank
|
||
Active, not recruiting |
NCT04228653 -
Long-Term Follow-up Safety After DDS Implantation With/Without CDNF Infusions
|
Phase 1/Phase 2 | |
Recruiting |
NCT05328492 -
Volume Mode Non-invasive Ventilation in Amyotrophic Lateral Sclerosis
|
N/A | |
Not yet recruiting |
NCT06151600 -
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
|
||
Recruiting |
NCT04880356 -
Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
|
||
Active, not recruiting |
NCT03609125 -
Cord Blood Serum in the Treatment of Neuro-Degenerative Ophthalmic Diseases. 1-Glaucoma
|
N/A | |
Recruiting |
NCT03153670 -
3T MRI in Patients With Deep Brain Stimulation (DBS)
|
N/A | |
Completed |
NCT03775538 -
Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT04635540 -
Decreased Empathy and Emotion Recognition in Patients With Neurodegenerative Disease
|
N/A |